Captrust Financial Advisors Mersana Therapeutics, Inc. Transaction History
Captrust Financial Advisors
- $38.8 Billion
- Q1 2025
A detailed history of Captrust Financial Advisors transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 31,134 shares of MRSN stock, worth $9,651. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,134Holding current value
$9,651% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding MRSN
# of Institutions
116Shares Held
101MCall Options Held
16.3KPut Options Held
13K-
Nextech Invest, Ltd. Zurich, V812.1MShares$3.74 Million0.97% of portfolio
-
Nextech Invest Ag12.1MShares$3.74 Million3.22% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA8.66MShares$2.69 Million0.99% of portfolio
-
Black Rock Inc. New York, NY8.38MShares$2.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.38MShares$2.6 Million0.0% of portfolio
About Mersana Therapeutics, Inc.
- Ticker MRSN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,169,296
- Market Cap $30.1M
- Description
- Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...